On May 9, 2014, Aeterna Zentaris, a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology, implemented a US$15 million ‘At the Market’ Common Share Offering Program under a prospectus supplement in the United States on the NASDAQ Capital Market.
Aeterna Zentaris intends to use the net proceeds from the offering to continue to fund its ongoing drug development activities, primarily for the advancement of its zoptarelin doxorubicin program, the marketing and commercialization of MACRILEN™ (assuming the FDA issues final approval in the expected timeframe), the potential in-licensing or acquisition of new commercial products, as well as for future negative cash flow, general corporate purposes and working capital. MLV & Co. LLC is the sole agent for the ATM offering.
Norton Rose Fulbright Canada LLP acted as lead counsel to Aeterna Zentaris. Norton Rose Fulbright’s team was led by Elliot Shapiro and included Catherine Simard and Meghan Stewart (Corporate and Securities).